Anti-PD-L1 antibodies, compositions and articles of manufacture
AssigneeGenentech, Inc.
InventorsBryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
Life of this patent
Estimating the term…
Abstract
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Claims61
An isolated heavy chain variable region polypeptide that specifically binds to PD-L1 comprising an HVR-H1, HVR-H2 and HVR-H3 sequence, wherein:
- (a)
- (SEQ ID NO:
- 1)
- the HVR-H1 sequence is GFTFSX1SWIH;
- (b)
- (SEQ ID NO:
- 2)
- the HVR-H2 sequence is AWIX2PYGGSX3YYADSVKG;
- (c)
- (SEQ ID NO:
- 3)
- the HVR-H3 sequence is RHWPGGFDY;
- further wherein:
- X1 is D or G;
- X2 is S or L;
- X3 is T or S.
An isolated anti-PD-L1 antibody or antigen binding fragment thereof, wherein the antibody or antibody fragment comprises a heavy chain and a light chain variable region sequence, wherein:
- (a) the heavy chain comprises an HVR-H1, HVR-H2 and HVR-H3, wherein further:
- (i)
- (SEQ ID NO:
- 1)
- the HVR-H1 sequence is GFTFSX1SWIH;
- (ii)
- (SEQ ID NO:
- 2)
- the HVR-H2 sequence is AWIX2PYGGSX3YYADSVKG;
- (iii)
- (SEQ ID NO:
- 3)
- the HVR-H3 sequence is RHWPGGFDY,;
- and
- (b) the light chain comprises an HVR-L1, HVR-L2 and HVR-L3, wherein further:
- (iv)
- (SEQ ID NOs:
- 8)
- the HVR-L1 sequence is RASQX4X5X6TX7X8A;
- (v)
- (SEQ ID NOs:
- 9)
- the HVR-L2 sequence is SASX9LX10S;
- (vi)
- (SEQ ID NOs:
- 10)
- the HVR-L3 sequence is QQX11X12X13X14PX15T;
- wherein:
- X1 is D or G;
- X2 is S or L;
- X3 is T or S;
- X4 may be D or V;
- X5 may be V or I;
- X6 may be S or N;
- X7 may be A or F;
- X8 may be V or L;
- X9 may be F or T;
- X10 may be Y or A;
- X11 may be Y, G, F, or S;
- X12 may be L, Y, F or W;
- X13 may be Y, N, A, T, G, F or I;
- X14 may be H, V, P, T or I;
- X15 may be A, W, R, P or T.
An isolated anti-PD-L1 antibody or antigen binding fragment thereof, wherein the antibody or antibody fragment comprises a heavy chain and light chain variable region sequence, wherein:
- (a) the heavy chain comprises the sequence:
- EVQLVESGGGLVQPGGSLRLS CAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVS A (SEQ ID NO:20), and
- (b) the light chain comprises the sequence:
- DIQMTQSPSSLSASVGDRVTITC RASQDVSTAVAWYQQKPGKAPKWYSASFLYSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQYLYH PATFGQGTKVEIKR (SEQ ID NO:21).
Dependencies are inferred from the claim text.